Bio-Path Holdings, Inc. (BPTH)
OTCMKTS
· Delayed Price · Currency is USD
0.210
0.00 (0.00%)
Feb 18, 2025, 4:00 PM EST
Bio-Path Holdings Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
796.78K
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| BioStem Technologies | 210.49M |
| SANUWAVE Health | 29.30M |
Bio-Path Holdings News
- 8 days ago - ARMISTICE CAPITAL, LLC Acquires Significant Stake in Bio-Path Holdings Inc - GuruFocus
- 9 days ago - Bio-Path Holdings Provides Key Clinical Updates - GlobeNewsWire
- 10 days ago - Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia - GlobeNewsWire
- 6 weeks ago - Bio-Path Holdings Provides 2025 Clinical and Operational Update - GlobeNewsWire
- 2 months ago - Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity - GlobeNewsWire
- 2 months ago - Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24 - Newsfile Corp
- 2 months ago - Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients - GlobeNewsWire
- 3 months ago - Bio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call Transcript - Seeking Alpha